Barinthus Biotherapeutics
Manufacturing · United Kingdom · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Zeus Building, 10 Rutherford Avenue Unit...Phone Number
+44 1865818808Website
www.barinthusbio.comRevenue
-Stock Symbol
BRNSIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Barinthus Biotherapeutics
Barinthus Biotherapeutics is a clinicalstage biopharmaceutical company focused on developing novel immunotherapies that guide the bodys T cells to treat chronic infectious diseases, autoimmune diseases, and inflammatory conditions. The firm leverages its proprietary platforms to create antigenspecific immunotherapeutic candidates designed to restore immune balance, suppress inappropriate immune responses, or stimulate targeted immunity against disease. Originally spun out of university and researchinstitution work, Barinthus has evolved beyond traditional vaccines and now emphasizes Tcell immunotherapy for conditions such as chronic viral infections, autoimmune disorders, and cancer. The companys mission centers on improving patient outcomes by using advanced immunology research to offer potentially transformative therapiesExplore more
Barinthus Biotherapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Barinthus Biotherapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Barinthus Biotherapeutics recently announced quarterly report
Check out if Barinthus Biotherapeutics is spiking on competitors!
Click to see if Barinthus Biotherapeutics had a recent Job posting/layoffs
Product Launch: Get notified when Barinthus Biotherapeutics launches new products
Congratulate Masked Content for being promoted to Masked Content at Barinthus Biotherapeutics
Barinthus Biotherapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Barinthus Biotherapeutics has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Barinthus Biotherapeutics has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Reach out to Masked Content who joined Barinthus Biotherapeutics as Masked Content
Find 2 more new buyers
Compare Similar Companies to Barinthus Biotherapeutics
Compare insights from companies similar to Barinthus Biotherapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Barinthus Biotherapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Barinthus Biotherapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Barinthus Biotherapeutics.
Barinthus Biotherapeutics Tech Stack
A closer look at the technologies used by Barinthus Biotherapeutics
See more technologies
Most Recent Scoops
Earnings
Earnings, Finance
Earnings
Earnings, Finance
Project
Laboratory Operations, Medical Research, Clinical Operations
New Hire
Executive Move
Executive Moves, New Hire
Earnings
Earnings, Finance
Barinthus Biotherapeutics News & Media
Barinthus Bio Reports Second Quarter 2026 Financial Results and Updates on Corporate Developments
GERMANTOWN, Md., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ: BRNS) (“Barinthus Bio,” or the “Company”), today announced its financial results for the quarter ended June 30, 2026, and provided an overview of the Company’s corporate developments. Barinthus Bio is an immunology and inflammation (“I&I”) company focused on developing therapies that promote immune tolerance with curative potential.Barinthus Bio Reports First Quarter 2026 Financial Results and Updates on Corporate Developments
GERMANTOWN, Md., April 30, 2026 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ: BRNS) (“Barinthus Bio,” or the “Company”), today announced its financial results for the quarter ended March 31, 2026, and provided an overview of the Company’s corporate developments. Barinthus Bio is an immunology and inflammation (“I&I”) company focused on developing therapies that promote immune tolerance with curative potential.Barinthus Bio Reports Full Year 2025 Financial Results and Updates on Corporate Developments
GERMANTOWN, Md., March 13, 2026 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ: BRNS) (“Barinthus Bio,” or the “Company”), today announced its financial results for the year ended December 31, 2025, and provided an overview of the Company’s corporate developments. Barinthus Bio is an immunology and inflammation (“I&I”) company focused on developing therapies that promote immune tolerance with curative potential.Barinthus Bio Announces Update on Phase 1 AVALON Clinical Trial of VTP-1000 for the Treatment of Celiac Disease
GERMANTOWN, Md., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ: BRNS) (“Barinthus Bio,” or the “Company”), an immunology and inflammation (“I&I”) company focused on developing immune tolerance therapies with curative potential, today announced an update on its first-in-human Phase 1 trial of VTP-1000 in adults with celiac disease. In the single ascending dose (“SAD”) portion of the trial, VTP-1000 was well tolerated with no treatment-related serious adverse events (“SAE
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Barinthus Biotherapeutics
Sign Up For FreeTo access detailed company insights
Barinthus Biotherapeutics is a clinicalstage biopharmaceutical company focused on developing novel immunotherapies that guide the bodys T cells to treat chronic infectious diseases, autoimmune diseases, and inflammatory conditions. The firm leverages its proprietary platforms to create antigenspecific immunotherapeutic candidates designed to restor... Read More
